Recent events
Recent events tied to this brand in public sources.
Back to profile32 entries · Page 1 of 2
2026
Moderna to be added to the Nasdaq-100 index
Per the morning briefing, Moderna is being added to the Nasdaq-100 index in pre-market trading on October 9, 2026.
2026
Moderna adds Chief Operating Officer role as company expands into oncology
Moderna has added a Chief Operating Officer role as the company expands into oncology, according to an AccessNewswire report.
2022
Alnylam files patent suits against Pfizer and Moderna
Alnylam said it separately filed suit against Pfizer and Moderna in a U.S. district court, seeking damages for alleged infringement of a patent in the manufacture and sale of their mRNA COVID-19 vaccines. Alnylam said it did not plan to seek an injunction or impede vaccine production, sale, or distribution.
2022
Alnylam sues Moderna and Pfizer over lipid patent
Alnylam filed lawsuits against Moderna and Pfizer in federal court in Delaware, alleging that their COVID-19 vaccines infringe its biodegradable-lipids patent. Alnylam said it was seeking monetary relief and did not want to impede vaccine sales, production or distribution. Moderna denied the allegation; Pfizer had not commented to the outlet.
2022
Genevant sues Moderna over vaccine-related patents
Moderna faced a US patent infringement lawsuit over lipid nanoparticle technology used in its Covid-19 vaccine. Genevant claims Moderna infringed technology covered by six US patents developed by Arbutus Biopharma and licensed to Genevant; Genevant is seeking royalties. Moderna denied the allegations and said it would defend itself in court.
2022
UQ partners with Moderna to develop mRNA vaccines
The University of Queensland partnered with Moderna to develop mRNA vaccines for a range of diseases. Under the arrangement, UQ researchers would identify antigens to trial, and Moderna would apply them to its mRNA platform for preclinical development by UQ.
2022
ROVI and Moderna expand manufacturing collaboration
ROVI and Moderna announced an expansion of their existing collaboration to manufacture mRNA medicines. The ten-year agreement includes investments in equipment and ROVI facilities and production lines in Spain; details were to be finalized in Q1.
2022
FDA grants full approval to Moderna's COVID-19 vaccine
The U.S. Food and Drug Administration granted full approval to Moderna's COVID-19 vaccine for the primary two-dose series in people aged 18 and older. The vaccine is marketed under the brand name Spikevax.
2022
FDA approves Spikevax for adults
The FDA granted full approval to Spikevax for active immunization to prevent COVID-19 in people 18 years of age and older. The article says the FDA is requiring Moderna to conduct postmarketing studies to further assess myocarditis and pericarditis risks.
2022
Moderna provides vaccine doses to Mexico
Moderna provided Mexico with 2.7 million doses of COVID-19 vaccine; the shipment arrived at Toluca Airport on Saturday, and the donated doses were to be used to inoculate teachers.
2021
FDA authorizes Pfizer and Moderna COVID-19 boosters for all adults
The FDA authorized COVID-19 booster shots for all adults from Pfizer and Moderna. The report said CDC action was still required before the shots could be administered to all adults.
2021
Moderna cuts 2021 vaccine sales forecast
Moderna cut its 2021 COVID-19 vaccine sales forecast, lowering its expected sales range from $20 billion to $15 billion–$18 billion. The article says the change was attributed in part to production and bottling constraints, longer international shipping lead times, and prioritization of deliveries to low-income countries.
2021
FDA authorizes Moderna and Johnson & Johnson COVID-19 boosters
The FDA authorized a third Moderna dose for seniors and other people at high risk, and said recipients of Johnson & Johnson's single-dose vaccine should receive a second dose at least two months after their first. The FDA also allowed eligible people to receive a booster from a different vaccine brand.
2021
Moderna and AbCellera launch antibody-development collaboration
Moderna and AbCellera announced a collaboration to develop mRNA-encoded antibody drugs, combining Moderna’s mRNA platform with AbCellera’s antibody discovery platform. AbCellera’s platform will identify antibodies against up to six targets selected by Moderna.
2021
Moderna collaborates with ILCM on rare-disease therapy
Moderna is donating its experimental mRNA-3351 therapy for Crigler-Najjar syndrome Type 1 to the Institute for Life Changing Medicines. Moderna will provide the therapy without upfront fees or downstream payments, and the institute will handle clinical development, with trials planned for 2022.
2021
Moderna and Lonza announce additional European vaccine production capacity
Moderna announced an additional agreement with Lonza to establish a production line at Lonza’s Geleen site in the Netherlands, planned to support an additional 300 million doses per year if the vaccine candidate is authorized.
2021
Moderna enters vaccine manufacturing agreement with Thermo Fisher
Moderna said it entered into an agreement with Thermo Fisher Scientific for manufacturing and packaging its Covid-19 vaccine. Thermo Fisher's Greenville, North Carolina site will provide fill/finish manufacturing services and packaging for hundreds of millions of doses.
2021
Ximedica and Moderna partner on mobile vaccine manufacturing prototype
Ximedica announced a partnership with Moderna to develop a prototype for rapid mobile manufacturing of vaccines and therapeutics as part of DARPA's NOW Program. Ximedica will receive up to $11 million in funding as part of the agreement.
2021
Baxter partners with Moderna on vaccine manufacturing
Baxter International and its BioPharma Solutions division partnered with Moderna to provide fill/finish sterile manufacturing services and packaging for approximately 60–90 million doses of Moderna's COVID-19 vaccine in 2021.
2021
Moderna announces vaccine production expansion and 2022 target
Moderna announced that it was expanding its in-house and partner COVID-19 vaccine production capabilities, with a 2022 production target of 1.4 billion doses.